What question did this study set out to answer?

To examine the genomic profile of Acute Myeloid Leukemia patients with co-mutations in DNMT3A and NPM1.

December 8, 2025Blood

DNMT3A and NPM1 co-mutations in Acute Myeloid Leukemia (AML): A genomic landscape study

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals unique genomic alterations in AML patients with DNMT3A and NPM1 co-mutations, suggesting important therapeutic implications.

To examine the genomic profile of Acute Myeloid Leukemia patients with co-mutations in DNMT3A and NPM1.
Analyzed 3,165 AML cases through comprehensive genomic profiling using hybrid capture DNA and RNA sequencing.
Evaluated individual genomic alterations, including FLT3, IDH1, IDH2, PTPN11, and TET2 in Co-mut+ cases.
7.7% of AML cases exhibited co-mutations in DNMT3A and NPM1.
Co-mut+ patients were typically older, more frequently female, and of European ancestry.
Elevated frequencies of FLT3 and IDH mutations were identified in Co-mut+ cases, while myelodysplastic mutations were more common in DNMT3A/NPM1 wild type.

Batayneh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis reveals unique genomic alterations in AML patients with DNMT3A and NPM1 co-mutations, suggesting important therapeutic implications.